| Backgrounds and objections:Cardiovascular disease usually represented with chronic progressive disease.With the progress of atherosclerosis and organ damage, cardiovascular disease gradually showed obvious clinical symptoms, Such as: coronary heart disease, myocardial infarction, heart failure, end-stage renal disease. The risk factors for cardiovascular disease was common in hypertension, diabetes, abnormal lipid metabolism, smoking, age, genetic factors. Hypertension ,which often lead to heart, brain, kidney and other organ complications ,was one of the world's most common cardiovascular diseases, and seriously endanger human health. With the improvement of living standard and social structure of the aging population, hypertension was more common than before, and significantly increased prevalence in China, about 160 million hypertension patients in China and meanwhile about 1 billion patients worldwide. Hypertension and it`s complications with high morbidity and mortality, controlling blood pressure had always been a basic prevention of cardiovascular disease mechanisms. Many experimental studies had demonstrated, renin-angiotensin system (RAS) played an important role in various stages of development of cardiovascular disease. Clinical studies in recent years had evidenced that, angiotensin receptor blocker (ARB) at different stages may slow down or block the development of cardiovascular disease. Although ARBs are with the same mechanism, according to their different pharmacological properties, clinical trials confirmed that ARBs also played significantly different roles in the prevention of cardiovascular disease. This article`s aim was ,through controlled with losartan in the trials,to assess the efficacy of Allisartan on antihypertensive and on the impact of serum uric acid and lipids, and to explore its possible mechanism.Method:Selected 38 patients with the age of 18-70 years old, and according to guidelines of hypertension in China in 2005 revised diagnostic criteria diagnosised of mild to moderate essential hypertension, as the studys. Who met the screening criteria after clean of drugs for 2 weeks were selected. The patients were randomly divided into two groups,20 cases in Allisartan group including 8 males and 12 females with the average age (62.3±5.7year) and 18 cases in Losartan group including 7 males and 11 females with the average age (63.2±5.4year). Allisartan group were given 240mg Allisartan (Ellis Shanghai Medical Technology Co., Ltd. Production) and losartan group were given 50mg losartan (Hangzhou MSD Pharmaceutical Co., Ltd. Production),once a day on the morning before breakfast for 12 weeks. During the experiment, blood pressure was measured at follow-up 0,2,4,8,12 weeks. Blood, urine, blood biochemistry (including liver function, kidney function, blood lipids, blood glucose and electrolytes) and 12-lead electrocardiogram before treatment and after 12 weeks of treatment were measured.Liver function, kidney function,urine and blood electrolytes were examed at 8 weeks in the treatment of routine. The detection of blood biochemistry indexes by automatic biochemical analyzer. Qualitative examination of clinical and experimental data to the number of cases (percentage) that the quantitative data as mean±standard deviation.Results:1. Effect on blood pressureBefore the treatment, 8 weeks and 12 weeks of treatment, experimental group and control group systolic and diastolic blood pressure compared, two groups for treatment 8 weeks and 12 weeks were significantly decreased blood pressure. Experimental group for 8 weeks treatment SBP / DBP decreased(25.5±8.3)/(12.5±7.0)mmHg, and for 12 weeks treatment SBP / DBP decreased(28.0±8.4)/(14.5±7.6)mmHg; control group for 8 weeks treatment SBP / DBP decreased(26.3±8.1)/(10.0±7.5)mmHg, and for 12 weeks treatment SBP / DBP decreased(28.8±7.9)/(13.0±7.8)mmHg.There were no significant difference between blood pressure of after 8 weeks and 12 weeks treatment. The same group for 12 weeks compared with 8 weeks blood pressure had decreased, but not statistically significant. After treatment of 8,12 weeks, blood pressure standard rate of Allisartan group were all 57.5% ,and Losartan group were 51.5% and 51.1%; There were no significant difference in standard rates between two groups . After treatment of 8,12 weeks, blood pressure efficient rate of Allisartan group were all 57.5% ,and Losartan group were 51.5% and 51.1%; There were no significant difference in efficient rates between two groups .So, the trail Showed that Allisartan and losartan had the same better blood pressure results. 2. Effect on the uric acidSerum uric acid in the two groups before treatment showed no significant difference (P> 0.05). Experimental group and control group after treatment of serum uric acid levels were significantly decreased with Statistically significant (P <0.05). Experimental group and control group after treatment was no significant difference (P> 0.05).3. Effect on the blood lipidThe two groups before treatment, serum lipids showed no significant difference (P> 0.05);experimental group and control group after treatment blood lipid levels change little with no statistically significant (P> 0.05).Conclusion:1. Allisartan and losartan on the treatment of mild and moderate hypertensive patients had similar blood pressure effect. Blood pressure of two groups for 8 weeks and 12 weeks treatment were significantly decreased; Allisartan 240mg in 8 weeks and 12 weeks of antihypertensive effects were good.2. Allisartan and losartan significantly decreased the serum uric acid level.3. Allisartan and losartan in patients with short-term treatment for mild to moderate hypertension, had little effect on lipid metabolism. But they may have improvement on lipid metabolism with a long-term treatment.
|
PDF Full Text Request